Navigation Links
International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
Date:9/27/2007

SINGAPORE, Sept. 27 /Xinhua-PRNewswire/ -- NeuroAid(TM) is the first natural compound to be studied in a large clinical trial focused on stroke recovery starting in the acute stage.

The CHIMES study is a multi-center double-blind placebo-controlled randomized trial to evaluate the efficacy of NeuroAid(TM) in reducing neurological deficit and improving independence in patients in rehabilitation, with treatment starting within 48 hours of a stroke. Already studied in a rehabilitation setting with initiation of treatment within 14 days of stroke incidence, NeuroAid(TM) will now be evaluated when administered in the acute stage, with periodic assessments for three months. The study will begin enrollment of 1,100 patients in early October 2007 at several hospitals in Singapore, followed by hospitals in the Philippines and in Thailand.

The study will be conducted by CHIMES Society, an international partnership of Key Opinion Leaders in stroke whose objective is to establish new stroke treatments.

Professor Marie-Germaine Bousser, Head of the Neurology Department at Lariboisiere Hospital in Paris, France and member of the Council of the American Stroke Association, commented, ''Recent drug trials in the acute treatment of stroke have unfortunately all been negative. It is thus very exciting to take a completely new approach and to scientifically test in different populations a compound that has long been used in Traditional Chinese Medicine.''

David Picard, CEO of Moleac, the Singapore/Biopolis-based global biopharmaceutical company that develops and markets NeuroAid(TM) outside of China, said: ''We are delighted at the interest NeuroAid(TM) has generated in the medical community worldwide. Over 200,000 patients in China alone are using NeuroAid(TM) every year, and patient feedback from other countries is very positive. Our next milestone is to generate clinical data in the acute phase, with studies that meet the standards of European and U.S
'/>"/>

SOURCE Moleac
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... ALBANY, New York , July 11, 2014 /PRNewswire/ ... published by Transparency Market Research "Endoscopy Devices Market (Endoscopes, ... Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019" the ... billion in 2012 and is expected to grow at ... reach an estimated value of USD 36.9 billion in ...
(Date:7/11/2014)... , July 11, 2014 ... to Safety & Health Expo 2014 were ... move to London , ... attending exhibition.          ... http://photos.prnewswire.com/prnh/20140711/696892-a )      (Photo: ...
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
(Date:7/11/2014)... Europe is one of the largest consumers of micro ... area. The agricultural sector is a significant user of ... the total water use. The scale and importance of ... far from negligible in most northern ones. , In ... the water use in most countries, while in the ...
(Date:7/11/2014)... July 11, 2014 Pigments are insoluble ... mainly three functions namely protective coating, opacity, and coloring. ... materials that impart color to substances such as paper, ... the pigments, which upon application impart color to the ... oxide, carbon black, and hematite. , The coloring action ...
(Date:7/11/2014)... Using electronic health records to understand the best available ... is more efficient and less costly for taxpayers than ... Research led by Professor van Staa, carried out while ... Datalink (CPRD) and who is now based at The ... Health Technology Assessment ( HTA ) today (Friday ...
(Date:7/11/2014)... Mexico (PRWEB) July 11, 2014 Experience ... the Mayan Heritage Experience Package at the luxury all-inclusive ... the package include a guided on-site ecological family tour ... well as The Coba Mayan Encounter Tour at the ... Nohoch Muul, the tallest pyramid in the Yucatan and ...
(Date:7/11/2014)... July 11, 2014 WWTrek Human Outreach ... Kilimanjaro Kids Community in Tanzania. Opened in 2012, the KKC ... and two cows. HOP Founder, Dean Cardinale, started the KKC ... of the orphaned children he encountered while running treks on ... the children, who have all made astounding progress in school ...
Breaking Medicine News(10 mins):Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3Health News:Better use of electronic health records makes clinical trials less expensive 2Health News:Explore the Aura and Mystery of the Yucatan’s Mayan Culture with New Hotel Package at AAA Five Diamond Grand Velas Riviera Maya 2Health News:Explore the Aura and Mystery of the Yucatan’s Mayan Culture with New Hotel Package at AAA Five Diamond Grand Velas Riviera Maya 3Health News:Human Outreach Project Sees Incredible Progress in the Kilimanjaro Kids Community 2
... have embarked on a multi-city tour offering passengers access to ... in New York, Boston and,Philadelphia, passengers in Washington, D.C. can ... *Passengers will be taken to any ... a maximum value of $25 per ride. , ...
... this phenomenon is tied to more aggressive disease, researchers say ... promote the growth of new nerves that are associated with ... that prostate cancer follows the growth of nerves, but this ... promote nerve growth, says a team at Baylor College of ...
... clots, researchers at the University of Oklahoma Health Sciences Center ... but seems to play a primary role in how cancer ... in recent issues of the journal Blood and ... research group at OU led by Patrick McKee first discovered ...
... behind the ravages of old age and in doing ... fighting cancer in younger persons can actually promote cancer ... biological cells stop dividing in response to stress or ... secretion of proteins that cause inflammation in neighboring cells ...
... Dec. 3 A patient who was surgically implanted,with ... promoted,by Medtronic, suffocated due to severe throat and neck ... and Page Perry, LLC who filed the lawsuit,in California ... The Complaint alleges, among other ...
... , ... (PRWEB) November 2, 2009 -- For the remainder of ... , to UK mainland addresses, excluding the highlands and islands, will be ... web site. , , ,Hyperdrug director Ben Watson says "Hyperdrug intends to ...
Cached Medicine News:Health News:The Makers of TYLENOL(R) Warming Liquids Offer Free 'Warming' Taxi Rides in Washington, D.C. 2Health News:Prostate Cancer Stimulates Nerve Growth 2Health News:Researchers discover new enzyme in cancer growth 2Health News:Cellular senescence a double-edged sword 2Health News:Cellular senescence a double-edged sword 3Health News:Cellular senescence a double-edged sword 4Health News:Cellular senescence a double-edged sword 5Health News:Medtronic, Inc. and Medtronic Sofamor Danek, USA, Inc. Sued for Product Liability and Promoting the Off-Label Use of Infuse(R) Bone Graft Product, According to Page Perry, LLC 2Health News:Beating the Credit Crunch with Hyperdrug.co.uk 2
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
Designed to use all advantages of bipolar technique. C-2600 MP recommended to all specialties that uses the benefits of the bipolar techniques....
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
NS2000 Bipolar Generator provides precise coagulation without tissue sticking....
Medicine Products: